Article Text

Download PDFPDF
Vascular brachytherapy versus sirolimus eluting stents for the treatment of in-stent restenosis: a prospective registry
  1. J J Goy1,
  2. P Urban3,
  3. C Seydoux1,
  4. P Couke2,
  5. E De Benedetti3,
  6. J C Stauffer1
  1. 1Cardiology Unit, Clinique Cecil, Lausanne, Switzerland
  2. 2Service of Radiotherapy, CHUV, Lausanne, Switzerland
  3. 3Hôpital de la Tour, Geneva, Switzerland
  1. Correspondence to:
    Dr J J Goy
    Department of Cardiology, Clinique Cecil, Avenue Ruchonnet 57, 1007 Lausanne, Switzerland;

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Since they were first introduced 17 years ago,1 bare metallic stents have improved the outcome of angioplasty.2 However, in-stent restenosis (ISR) remains a major limitation with an incidence of additional revascularisation of 17–21 %. Among the several approaches proposed to address this problem, vascular brachytherapy (VBT) has given the best results, with an incidence of major cardiac events at nine months from 18–28 %.3 The preliminary results reported with the use of sirolimus eluting stents (SES) in de novo lesions were encouraging.4 We report our results with both techniques in patients with ISR.


Between April 2001 and mid April 2002 all patients with ISR were treated with VBT, and from mid April to November 2002 they received one or several SES within the previous stent. The data from these patients were included in a prospective registry. All patients were pre-treated with aspirin 100 mg/day. Intravenous heparin was given initially and a 300 …

View Full Text